Fintel reports that on March 10, 2026, Raymond James upgraded their outlook for Dianthus Therapeutics (NasdaqCM:DNTH) from Outperform to Strong Buy.
Analyst Price Forecast Suggests 11.59% Downside
As of February 25, 2026, the average one-year price target for Dianthus Therapeutics is $76.76/share. The forecasts range from a low of $47.47 to a high of $131.25. The average price target represents a decrease of 11.59% from its latest reported closing price of $86.82 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Dianthus Therapeutics is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is 0.02.
What is the Fund Sentiment?
There are 212 funds or institutions reporting positions in Dianthus Therapeutics. This is an decrease of 67 owner(s) or 24.01% in the last quarter. Average portfolio weight of all funds dedicated to DNTH is 0.47%, an increase of 18.13%. Total shares owned by institutions increased in the last three months by 1.29% to 49,554K shares. 
The put/call ratio of DNTH is 1.02, indicating a bearish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 2,503K shares representing 5.79% ownership of the company. In its prior filing, the firm reported owning 2,578K shares , representing a decrease of 2.98%. The firm decreased its portfolio allocation in DNTH by 85.58% over the last quarter.
Octagon Capital Advisors holds 2,417K shares representing 5.59% ownership of the company. No change in the last quarter.
Fairmount Funds Management holds 2,137K shares representing 4.94% ownership of the company. In its prior filing, the firm reported owning 3,307K shares , representing a decrease of 54.74%. The firm decreased its portfolio allocation in DNTH by 42.75% over the last quarter.
Avidity Partners Management holds 2,104K shares representing 4.87% ownership of the company. In its prior filing, the firm reported owning 3,204K shares , representing a decrease of 52.28%. The firm decreased its portfolio allocation in DNTH by 12.84% over the last quarter.
TCG Crossover Management holds 1,677K shares representing 3.88% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
